Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

Autologus Hematopoietic Stem Cell Transplant in Type 1 Diabetes Mellitus in a Nonmyeloablative and Outpatient Setting

Olga Graciela Cantú-Rodríguez, MD, Fernando Lavalle-Gonzalez, MD, Miguel Angel Herrera-Rojas, MD, Cesar H Gutiérrez-Aguirre, MD, Consuelo Mancías-Guerra, MD, Jose Carlos Jaime-Pérez, MD, Oscar Gonzalez-Llano, MD, Alfonso Zapata-Garrido, MD, Jesus Zacarias Villarreal-Perez, MD, David Gomez-Almaguer, MD

Blood (2014) 124 (21): 1191.

https://doi.org/10.1182/blood.V124.21.1191.1191

Published: 2014

Journal Articles

Eltrombopag and high-dose dexamethasone as frontline treatment of newly diagnosed immune thrombocytopenia in adults

David Gómez-Almaguer, Miguel A. Herrera-Rojas, José C. Jaime-Pérez, Andrés Gómez-De León, Olga G. Cantú-Rodríguez, César H. Gutiérrez-Aguirre, Luz Tarín-Arzaga, Jesús Hernández-Reyes, Guillermo J. Ruiz-Arguelles

Blood (2014) 123 (25): 3906–3908.

https://doi.org/10.1182/blood-2014-01-549360

Published: 2014

Journal Articles

Low-Dose Nilotinib and Imatinib Combination In CML Patients, With Failure, Suboptimal Response Or Treatment Intolerance To First Line Imatinib Treatment. A Pilot Study

David Gomez-Almaguer, MD, Roxana Saldaña-Vázquez, MD, Olga Graciela Cantú-Rodríguez, MD, Cesar H Gutiérrez-Aguirre, MD, Jose Carlos Jaime-Pérez, MD, Luz C. Tarin-Arzaga, MD

Blood (2013) 122 (21): 4034.

https://doi.org/10.1182/blood.V122.21.4034.4034

Published: 2013

Journal Articles

Eltrombopag and High-Dose Dexamethasone As First Line Treatment For ITP

David Gomez-Almaguer, MD, Miguel Angel Herrera-Rojas, MD, Andres Gomez-de Leon, MD, Olga Graciela Cantú-Rodríguez, MD, Cesar H Gutiérrez-Aguirre, MD, Jose Carlos Jaime-Pérez, MD, Luz C. Tarin-Arzaga, MD, Guillermo J. Ruiz-Arguelles, MD, FRCP (Glasg), MACP, Jesus Hernandez-Reyes, MD

Blood (2013) 122 (21): 3544.

https://doi.org/10.1182/blood.V122.21.3544.3544

Published: 2013

Journal Articles

Subsequent Malignant Neoplasms After Allogeneic Hematopoietic Stem Cell Transplantation Using Reduced-Intensity Conditioning and Outpatient Conduction

Gabriela Zamora-Ortiz, MD, Sara Velazquez-Sanchez-de-Cima, MD, Sergio Ponce-de-Leon, MD, César H. Gutiérrez-Aguirre, MD, Guillermo J. Ruiz-Delgado, MD, David Gomez-Almaguer, MD, Guillermo J. Ruiz-Arguelles, MD, FRCP, (Glasg), MACP

Blood (2013) 122 (21): 5502.

https://doi.org/10.1182/blood.V122.21.5502.5502

Published: 2013

Journal Articles

Alemtuzumab in the Treatment of Steroid Refractory Acute Graft-Versus-Host Disease.

David Gomez-Almaguer, Guillermo Ruiz-Arguelles, Oscar Gonzalez-Llano, Olga G. Cantu, Cesar H. Gutierrez, Jose Carlos Jaime-Perez, Luz Tarin-Arzaga, Sergio Giralt

Blood (2006) 108 (11): 5294.

https://doi.org/10.1182/blood.V108.11.5294.5294

Published: 2006

Journal Articles

The Early Referral for Reduced-Intensity Stem Cell Transplantation in Patients with Ph1 (+) Chronic Myelogenous Leukemia in Chronic Phase in the Imatinib Era: Results of the Latin American Cooperative Oncohematology Group (LACOHG) Prospective, Multicenter Study.

Guillermo J. Ruiz-Arguelles, MD, FACP, FRCP(Glasg), David Gomez-Almaguer, MD, Amelia Morales-Toquero, MD, Cesar H. Gutierrez-Aguirre, Jorge Vela-Ojeda, Miriam A. Garcia-Ruiz-Esparza, MD, Carlos Manzano, MD, Amado Karduss, MD, Abraham Sumoza, MD, Carmino de-Souza, MD, Eliana Miranda, MD, Sergio Giralt, MD

Blood (2005) 106 (11): 4838.

https://doi.org/10.1182/blood.V106.11.4838.4838

Published: 2005

NARROW

Autologus Hematopoietic Stem Cell Transplant in Type 1 Diabetes Mellitus in a Nonmyeloablative and Outpatient Setting

Eltrombopag and high-dose dexamethasone as frontline treatment of newly diagnosed immune thrombocytopenia in adults

Low-Dose Nilotinib and Imatinib Combination In CML Patients, With Failure, Suboptimal Response Or Treatment Intolerance To First Line Imatinib Treatment. A Pilot Study

Eltrombopag and High-Dose Dexamethasone As First Line Treatment For ITP

Subsequent Malignant Neoplasms After Allogeneic Hematopoietic Stem Cell Transplantation Using Reduced-Intensity Conditioning and Outpatient Conduction

Alemtuzumab in the Treatment of Steroid Refractory Acute Graft-Versus-Host Disease.

The Early Referral for Reduced-Intensity Stem Cell Transplantation in Patients with Ph1 (+) Chronic Myelogenous Leukemia in Chronic Phase in the Imatinib Era: Results of the Latin American Cooperative Oncohematology Group (LACOHG) Prospective, Multicenter Study.

Email alerts

ASH Publications

American Society of Hematology

Autologus Hematopoietic Stem Cell Transplant in Type 1 Diabetes Mellitus in a Nonmyeloablative and Outpatient Setting

Eltrombopag and high-dose dexamethasone as frontline treatment of newly diagnosed immune thrombocytopenia in adults

Low-Dose Nilotinib and Imatinib Combination In CML Patients, With Failure, Suboptimal Response Or Treatment Intolerance To First Line Imatinib Treatment. A Pilot Study

Eltrombopag and High-Dose Dexamethasone As First Line Treatment For ITP

Subsequent Malignant Neoplasms After Allogeneic Hematopoietic Stem Cell Transplantation Using Reduced-Intensity Conditioning and Outpatient Conduction

Alemtuzumab in the Treatment of Steroid Refractory Acute Graft-Versus-Host Disease.

The Early Referral for Reduced-Intensity Stem Cell Transplantation in Patients with Ph1 (+) Chronic Myelogenous Leukemia in Chronic Phase in the Imatinib Era: Results of the Latin American Cooperative Oncohematology Group (LACOHG) Prospective, Multicenter Study.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only